ライフサイエンスコーパス: obstructive pulmonary disease

1 ing, 0.51 for diabetes, and 0.69 for chronic obstructive pulmonary disease).

2 an PH (idiopathic or associated with chronic obstructive pulmonary disease).

3 s index, chronic kidney disease, and chronic obstructive pulmonary disease).

4 le effect modification by asthma and chronic obstructive pulmonary disease.

5 nostic and therapeutic approaches in chronic obstructive pulmonary disease.

6 patients with acute exacerbation of chronic obstructive pulmonary disease.

7 en demonstrated yet in patients with chronic obstructive pulmonary disease.

8 g, which is the main risk factor for chronic obstructive pulmonary disease.

9 o exercise training in patients with chronic obstructive pulmonary disease.

10 his might indicate an early stage of chronic obstructive pulmonary disease.

11 , including cystic fibrosis (CF) and chronic obstructive pulmonary disease.

12 V), and medical history of asthma or chronic obstructive pulmonary disease.

13 tion therapy in patients with severe chronic obstructive pulmonary disease.

14 lying inflammatory diseases, such as chronic obstructive pulmonary disease.

15 ents an early developmental phase of chronic obstructive pulmonary disease.

16 be a cofactor in the development of chronic obstructive pulmonary disease.

17 erbations in patients suffering from chronic obstructive pulmonary disease.

18 ifically exacerbations of asthma and chronic obstructive pulmonary disease.

19 mortality from cirrhosis, cancer, or chronic obstructive pulmonary disease.

20 s an inhaled treatment of asthma and chronic obstructive pulmonary disease.

21 d infection are the major drivers of chronic obstructive pulmonary disease.

22 tory tract infections in adults with chronic obstructive pulmonary disease.

23 s afflicted with cystic fibrosis and chronic obstructive pulmonary disease.

24 nally over 10 years from adults with chronic obstructive pulmonary disease.

25 ditionally occurring in men, such as chronic obstructive pulmonary disease.

26 ergic receptor agonist used to treat chronic obstructive pulmonary disease.

27 ce of other airway diseases, such as chronic obstructive pulmonary disease.

28 rbations of both cystic fibrosis and chronic obstructive pulmonary disease.

29 re of several lung pathologies, e.g. chronic obstructive pulmonary disease.

30 goals of treatment for patients with chronic obstructive pulmonary disease.

31 ial aggregation, and associated with chronic obstructive pulmonary disease.

32 morbidities included diabetes (21%), chronic obstructive pulmonary disease (12%), and immunosuppressi

33 ronary artery disease (15.6%-22.3%), chronic obstructive pulmonary disease (14.4%-20.1%), anemia (12.

34 (27.4%), diabetes mellitus (29.5%), chronic obstructive pulmonary disease (16.0%), and a mean logist

35 redicting the inception of asthma or chronic obstructive pulmonary disease, (2) inflammatory phenotyp

36 tia with frailty (29%), frailty with chronic obstructive pulmonary disease (25%), and frailty with di

37 omyopathy (86% versus 52%; P=0.002), chronic obstructive pulmonary disease (41% versus 13%; P=0.001),

38 c surgery (18% versus 12%, P<0.001), chronic obstructive pulmonary disease (5% versus 3%, P=0.004), u

39 nsion (53.5%), diabetes (22.3%), and chronic obstructive pulmonary disease (9.4%).

40 enesis of prevalent diseases such as chronic obstructive pulmonary disease, acquired rhinosinusitis,

41 Airflow limitation compatible with chronic obstructive pulmonary disease affects almost one-third o

42 In this study, we use a model of chronic obstructive pulmonary disease airway disease utilizing a

43 of heart failure, moderate-to-severe chronic obstructive pulmonary disease, airway patency problems,

44 ical ventilation; moderate to severe chronic obstructive pulmonary disease; airway patency problems;

45 as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease, although the factors that

46 n contrast, the higher prevalence of chronic obstructive pulmonary disease among Puerto Ricans and Cu

47 sease (HR 1.59, 95 % CI: 1.33-1.90), chronic obstructive pulmonary disease and bronchiectasis (HR 1.5

48 l admissions in patients with severe chronic obstructive pulmonary disease and chronic bronchitis who

49 s with chronic lung disease, such as chronic obstructive pulmonary disease and cystic fibrosis, exhib

50 Twenty-two ex-smokers with combined chronic obstructive pulmonary disease and heart failure with red

51 finding in patients with coexistent chronic obstructive pulmonary disease and heart failure.

52 end-stage pulmonary diseases such as chronic obstructive pulmonary disease and idiopathic pulmonary f

53 d in the quadriceps of patients with chronic obstructive pulmonary disease and intensive care unit-ac

54 diseases as varied phenotypically as chronic obstructive pulmonary disease and IPF and suggest that t

55 major site of airflow obstruction in chronic obstructive pulmonary disease and may precede emphysema

56 , drug use disorders, and history of chronic obstructive pulmonary disease and occupational lung dise

57 evelops in many patients with chronic severe obstructive pulmonary disease and other advanced lung di

58 primarily in central Appalachia for chronic obstructive pulmonary disease and pneumoconiosis; widely

59 d with the susceptibility to develop chronic obstructive pulmonary disease and pulmonary function lev

60 eart failure, stroke, pneumonia, and chronic obstructive pulmonary disease) and a surgical diagnosis

61 ing ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and cancers (liver, stoma

62 with failure to rescue were ascites, chronic obstructive pulmonary disease, and diabetes.

63 en, sodium, cerebrovascular disease, chronic obstructive pulmonary disease, and hemoglobin, was a pow

64 acute respiratory distress syndrome, chronic obstructive pulmonary disease, and interstitial lung dis

65 dy mass index, polyvascular disease, chronic obstructive pulmonary disease, and malignancy.

66 th idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease, and mice with bleomycin-,

67 36 cases of asthma, 298,751 cases of chronic obstructive pulmonary disease, and more than 1.1 million

68 0-mug/m3 increase) with respiratory, chronic obstructive pulmonary disease, and pneumonia mortality,

69 tory lung diseases including asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis.

70 role in the pathogenesis of asthma, chronic obstructive pulmonary disease, and pulmonary infection.

71 Older participants, those with chronic obstructive pulmonary disease, and those with more than

72 ortion (25% to 45%) of patients with chronic obstructive pulmonary disease are never-smokers, most ge

73 opathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease are usually studied in iso

74 veolar macrophages (AM) are found in chronic obstructive pulmonary disease, asthma, cystic fibrosis,

75 morbidities including renal disease, chronic obstructive pulmonary disease, atrial fibrillation, hear

76 3p/5p were elevated in patients with chronic obstructive pulmonary disease but more markedly in patie

77 ventilated patients with asthma and chronic obstructive pulmonary disease, but are not recommended f

78 diseases, particularly in asthma and chronic obstructive pulmonary disease, but their potential role

79 lesterol, stroke, arthritis, asthma, chronic obstructive pulmonary disease, cancer, weak/failing kidn

80 astatin group (atrial septal defect, chronic obstructive pulmonary disease, chest pain, diverticuliti

81 ars or older with severe/very severe chronic obstructive pulmonary disease, chronic bronchitis, two o

82 n, New York Heart Association class, chronic obstructive pulmonary disease, chronic kidney disease, N

83 pertension, cerebrovascular disease, chronic obstructive pulmonary disease, chronic renal failure, pr

84 adults with asthma were as follows: chronic obstructive pulmonary disease (COPD) (13.4% vs 3.1%), de

85 Chronic obstructive pulmonary disease (COPD) affects over 65 mil

86 ges in gene expression that occur in chronic obstructive pulmonary disease (COPD) after corticosteroi

87 rticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) and a history of ex

88 NSCLC) patients, human patients with chronic obstructive pulmonary disease (COPD) and amyotrophic lat

89 expression in lungs of patients with chronic obstructive pulmonary disease (COPD) and asthma compared

90 atients with characteristics of both chronic obstructive pulmonary disease (COPD) and asthma, named a

91 obstructive lung diseases including chronic obstructive pulmonary disease (COPD) and cystic fibrosis

92 Patients with chronic obstructive pulmonary disease (COPD) and in particular s

93 To determine how chronic obstructive pulmonary disease (COPD) and mechanical vent

94 piratory stimulant for patients with chronic obstructive pulmonary disease (COPD) and metabolic alkal

95 own efficacy in patients with stable chronic obstructive pulmonary disease (COPD) and resting or exer

96 Worldwide, chronic obstructive pulmonary disease (COPD) and stroke are lead

97 Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalen

98 ng persistent airway inflammation in chronic obstructive pulmonary disease (COPD) are incompletely un

99 nist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.

100 Patients with chronic obstructive pulmonary disease (COPD) are susceptible to

101 interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are unknown.

102 established complication of advanced chronic obstructive pulmonary disease (COPD) associated with inc

103 city of studies comparing asthma and chronic obstructive pulmonary disease (COPD) based on thoracic q

104 nia (CAP) incidence in patients with chronic obstructive pulmonary disease (COPD) by unknown mechanis

105 al lung ventilation in patients with chronic obstructive pulmonary disease (COPD) by using free-breat

106 Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely

107 Chronic obstructive pulmonary disease (COPD) comprises chronic b

108 ic signaling networks in healthy and chronic obstructive pulmonary disease (COPD) contexts.

109 uency of ILC1 cells in patients with chronic obstructive pulmonary disease (COPD) correlated with dis

110 susceptible regions have effects on chronic obstructive pulmonary disease (COPD) development, while

111 tal with signs and symptoms of acute chronic obstructive pulmonary disease (COPD) exacerbation.

112 lood eosinophils are associated with chronic obstructive pulmonary disease (COPD) exacerbations among

113 he leading bacterial pathogen during chronic obstructive pulmonary disease (COPD) exacerbations and i

114 ng noninvasive ventilation (NIV) for chronic obstructive pulmonary disease (COPD) exacerbations, heli

115 harmaceutical industry, and academic chronic obstructive pulmonary disease (COPD) experts with adviso

116 RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) frequently have alb

117 Since Chronic Obstructive Pulmonary disease (COPD) has emerged as a ce

118 patients with features of asthma and chronic obstructive pulmonary disease (COPD) has highlighted the

119 other respiratory conditions such as chronic obstructive pulmonary disease (COPD) has not been invest

120 to inhaled therapy by patients with chronic obstructive pulmonary disease (COPD) has not been report

121 f eosinophils in blood and sputum in chronic obstructive pulmonary disease (COPD) have been associate

122 People with advanced chronic obstructive pulmonary disease (COPD) have distressing ph

123 n smoking behavior and lung function/chronic obstructive pulmonary disease (COPD) have not been syste

124 hese particles to infect healthy and chronic obstructive pulmonary disease (COPD) human ciliated resp

125 d number of deaths among people with chronic obstructive pulmonary disease (COPD) in England and Scot

126 ntified as a susceptibility gene for chronic obstructive pulmonary disease (COPD) in genome-wide asso

127 (EMPs) are emerging as biomarkers of chronic obstructive pulmonary disease (COPD) in individuals expo

128 ciation between childhood asthma and chronic obstructive pulmonary disease (COPD) in later life has b

129 The association of asthma and chronic obstructive pulmonary disease (COPD) in the same patient

130 The burden of chronic obstructive pulmonary disease (COPD) in the USA continue

131 RATIONALE: Acute exacerbations of chronic obstructive pulmonary disease (COPD) increase the risk o

132 RATIONALE: Chronic obstructive pulmonary disease (COPD) is a chronic, progr

133 Chronic obstructive pulmonary disease (COPD) is a complex and he

134 Chronic obstructive pulmonary disease (COPD) is a complex and he

135 Chronic obstructive pulmonary disease (COPD) is a complex diseas

136 Chronic obstructive pulmonary disease (COPD) is a condition char

137 Chronic obstructive pulmonary disease (COPD) is a devastating di

138 Chronic obstructive pulmonary disease (COPD) is a global health

139 Chronic obstructive pulmonary disease (COPD) is a leading cause

140 Chronic obstructive pulmonary disease (COPD) is a leading cause

141 Chronic obstructive pulmonary disease (COPD) is a risk factor fo

142 Chronic obstructive pulmonary disease (COPD) is associated with

143 Chronic obstructive pulmonary disease (COPD) is characterized by

144 Chronic obstructive pulmonary disease (COPD) is characterized by

145 Chronic obstructive pulmonary disease (COPD) is characterized by

146 Chronic obstructive pulmonary disease (COPD) is characterized by

147 Chronic obstructive pulmonary disease (COPD) is characterized by

148 RATIONALE: Chronic obstructive pulmonary disease (COPD) is characterized by

149 s contributing to the development of chronic obstructive pulmonary disease (COPD) is crucial for deve

150 RATIONALE: The prevalence of chronic obstructive pulmonary disease (COPD) is increasing faste

151 RATIONALE: The burden of chronic obstructive pulmonary disease (COPD) is increasing, yet

152 mic inflammation among patients with chronic obstructive pulmonary disease (COPD) is largely unknown.

153 Chronic obstructive pulmonary disease (COPD) is linked to both c

154 RATIONALE: Chronic obstructive pulmonary disease (COPD) is often unrecogniz

155 Chronic obstructive pulmonary disease (COPD) is regarded as a di

156 clinical relevance in patients with chronic obstructive pulmonary disease (COPD) is scarce.

157 With increasingly aging populations, chronic obstructive pulmonary disease (COPD) is the fourth leadi

158 del of cigarette smoke (CS) -induced chronic obstructive pulmonary disease (COPD) is the primary test

159 Chronic obstructive pulmonary disease (COPD) is the third leadin

160 The role of fibrocytes in chronic obstructive pulmonary disease (COPD) is unknown.

161 Dyspnoea in chronic obstructive pulmonary disease (COPD) may be linked to th

162 Epidemiologic evidence suggested chronic obstructive pulmonary disease (COPD) might increase risk

163 Chronic obstructive pulmonary disease (COPD) occurs in a minorit

164 Chronic obstructive pulmonary disease (COPD) often coexists with

165 acts in order to study the effect of Chronic Obstructive Pulmonary Disease (COPD) on the lung barrier

166 bjects (99%) were assigned as having chronic obstructive pulmonary disease (COPD) or no COPD.

167 Some of the Chronic Obstructive Pulmonary Disease (COPD) patients engaged in

168 al infection; however, in asthma and chronic obstructive pulmonary disease (COPD) patients, this viru

169 y exacerbation risk in patients with chronic obstructive pulmonary disease (COPD) rely on a history o

170 Many individuals with chronic obstructive pulmonary disease (COPD) remain undiagnosed

171 erging models for predicting risk of chronic obstructive pulmonary disease (COPD) require external va

172 Currently, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a ratio of

173 Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute non

174 s known about the natural history of chronic obstructive pulmonary disease (COPD) that has developed

175 t-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high ris

176 nsplantation (n = 11) and those with chronic obstructive pulmonary disease (COPD) who were undergoing

177 Patients with chronic obstructive pulmonary disease (COPD) with an eosinophili

178 ted in patients with asthma and that chronic obstructive pulmonary disease (COPD), a condition simila

179 armacological treatment decisions in chronic obstructive pulmonary disease (COPD), a personalized app

180 ent (52 of 78) of patients exhibited chronic obstructive pulmonary disease (COPD), although only 19 h

181 spiratory diseases including asthma, chronic obstructive pulmonary disease (COPD), and critical illne

182 f US adults aged 40 to 79 years have chronic obstructive pulmonary disease (COPD), and it is the thir

183 Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and lung infection

184 dental cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), and lung-cancer mo

185 infections (ARI), asthma, pneumonia, chronic obstructive pulmonary disease (COPD), and upper respirat

186 Most airway diseases, including chronic obstructive pulmonary disease (COPD), are associated wit

187 in identifying subphenotypes within chronic obstructive pulmonary disease (COPD), asthma, and other

188 s are important in the management of chronic obstructive pulmonary disease (COPD), but can slightly i

189 erved in the airway in patients with chronic obstructive pulmonary disease (COPD), but their clinical

190 (HIV) are features of HIV-associated chronic obstructive pulmonary disease (COPD), but these changes

191 RATIONALE: Chronic obstructive pulmonary disease (COPD), in particular emph

192 In chronic obstructive pulmonary disease (COPD), lymphoid follicles

193 bined and for heart disease, cancer, chronic obstructive pulmonary disease (COPD), stroke, unintentio

194 RATIONALE: In chronic obstructive pulmonary disease (COPD), the benefits of pu

195 betes, hyperlipidemia, hypertension, chronic obstructive pulmonary disease (COPD), ulcer history, use

196 In applying CONDOR to eQTLs in chronic obstructive pulmonary disease (COPD), we found the globa

197 older individuals and in those with chronic obstructive pulmonary disease (COPD), whereas shorter-te

198 of a 63-year-old man suffering from chronic obstructive pulmonary disease (COPD), who presented with

199 ied by the tumor-enhancing effect of chronic obstructive pulmonary disease (COPD)-type airway inflamm

200 cation of gene expression studies in chronic obstructive pulmonary disease (COPD).

201 e predicted of FEV1 in patients with chronic obstructive pulmonary disease (COPD).

202 ors and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD).

203 associated with worse outcomes than chronic obstructive pulmonary disease (COPD).

204 tion has been studied in relation to chronic obstructive pulmonary disease (COPD).

205 ssive respiratory diseases including chronic obstructive pulmonary disease (COPD).

206 lung structure in conditions such as chronic obstructive pulmonary disease (COPD).

207 ise intolerance are common in severe chronic obstructive pulmonary disease (COPD).

208 (HHIP) are robustly associated with chronic obstructive pulmonary disease (COPD).

209 Exacerbations are a hallmark of chronic obstructive pulmonary disease (COPD).

210 associated emphysema, a component of chronic obstructive pulmonary disease (COPD).

211 es exercise hyperpnoea in health and chronic obstructive pulmonary disease (COPD).

212 mptomatic smokers, and patients with chronic obstructive pulmonary disease (COPD).

213 ered concurrently as determinants of chronic obstructive pulmonary disease (COPD).

214 RNAs in lung tissue of patients with chronic obstructive pulmonary disease (COPD).

215 ssociated with cigarette smoking and chronic obstructive pulmonary disease (COPD).

216 arrier to the effective treatment of chronic obstructive pulmonary disease (COPD).

217 emphysematous lungs of patients with chronic obstructive pulmonary disease (COPD).

218 ronic hypoxemia in disorders such as chronic obstructive pulmonary disease (COPD).

219 f physical activity in the course of chronic obstructive pulmonary disease (COPD).

220 of airway infections associated with chronic obstructive pulmonary disease (COPD).

221 nd are essential to the diagnosis of chronic obstructive pulmonary disease (COPD).

222 idity and mortality in patients with chronic obstructive pulmonary disease (COPD).

223 e is involved in the pathogenesis of chronic obstructive pulmonary disease (COPD).

224 herapeutic agent in the treatment of chronic obstructive pulmonary disease (COPD).

225 mation and airway wall remodeling in chronic obstructive pulmonary disease (COPD).

226 ons for select conditions, including chronic obstructive pulmonary disease (COPD).

227 teroid efficacy in the management of chronic obstructive pulmonary disease (COPD).

228 ae (NTHi) persists in the airways in chronic obstructive pulmonary disease (COPD).

229 activity is a key therapeutic aim in chronic obstructive pulmonary disease (COPD).

230 ors and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD).

231 own to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD).

232 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

233 a whole-lung basis in patients with chronic obstructive pulmonary disease (COPD).

234 impairment that was consistent with chronic obstructive pulmonary disease (COPD); these participants

235 ith comorbid allergy (P = 0.045) and chronic obstructive pulmonary disease (COPD; P = 0.015).

236 or lung cancer (LC; P=4.0 x 10(-4)), chronic obstructive pulmonary disease (COPD; P=9.3 x 10(-4)), pe

237 ammatory diseases such as asthma and chronic obstructive pulmonary diseases (COPD) affect more than o

238 he COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease [COPD]; non-Hispanic white

239 ckage to the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) study to examin

240 r are necessary parameters to detect chronic obstructive pulmonary diseases (COPDs) such as asthma, b

241 line age, body mass index, diabetes, chronic obstructive pulmonary disease, coronary artery disease,

242 among smokers and is associated with chronic obstructive pulmonary disease development and progressio

243 onary artery disease, heart failure, chronic obstructive pulmonary disease, diabetes mellitus, nitrat

244 actors for the various phenotypes of chronic obstructive pulmonary disease during different stages of

245 hnicity, education, body mass index, chronic obstructive pulmonary disease, emphysema, personal histo

246 nic lung diseases such as asthma and chronic obstructive pulmonary disease, estimating physiologic im

247 stantial proportion of patients with chronic obstructive pulmonary disease, even after smoking cessat

248 eve better outcomes of patients with chronic obstructive pulmonary disease exacerbation treated with

249 utcomes among patients with an acute chronic obstructive pulmonary disease exacerbation.

250 RATIONALE: Chronic obstructive pulmonary disease exacerbations are associat

251 s linked to asthma exacerbations and chronic obstructive pulmonary disease exacerbations in adults.

252 Pharmacologic treatment of chronic obstructive pulmonary disease has consistent beneficial

253 NALE: Genetic association studies in chronic obstructive pulmonary disease have primarily tested for

254 r exercise ventilatory efficiency in chronic obstructive pulmonary disease-heart failure overlap.

255 HR, 1.66; 95% CI, 1.41-1.95), severe chronic obstructive pulmonary disease (HR, 1.39; 95% CI, 1.25-1.

256 s for asthma in children and adults, chronic obstructive pulmonary disease, hypertension, diabetes, o

257 6 million to 6.8 million) DALYs from chronic obstructive pulmonary disease in 2015.

258 ary disease, left heart failure, and chronic obstructive pulmonary disease in not-operated patients.

259 ed self-management for patients with chronic obstructive pulmonary disease in primary care.

260 ve lung diseases, such as asthma and chronic obstructive pulmonary disease, include not only diagnost

261 ffecting the lung, including asthma, chronic obstructive pulmonary disease, infections, and cancer.

262 ed the transcriptional repertoire of chronic obstructive pulmonary disease, IPF, or normal histology

263 Chronic obstructive pulmonary disease is characterized, in part,

264 BACKGROUND AND Chronic obstructive pulmonary disease is increasing in prevalenc

265 hed at birth and predisposes them to chronic obstructive pulmonary disease later in life.

266 rt disease, cerebrovascular disease, chronic obstructive pulmonary disease, lung cancer, and lower re

267 s: a small asthma cohort and a large chronic obstructive pulmonary disease metaanalysis cohort.

268 sk factor profile but with increased chronic obstructive pulmonary disease, migraine, and affective d

269 nflammatory disease models including chronic obstructive pulmonary disease, multiple sclerosis, and s

270 nity settings to limit the impact of chronic obstructive pulmonary disease on everyday life of indivi

271 sease (OR, 0.46; 95% CI, 0.36-0.59), chronic obstructive pulmonary disease (OR, 0.62; 95% CI, 0.52-0.

272 5; 95% CI, 1.12-1.39; P < .001), and chronic obstructive pulmonary disease (OR, 1.26; 95% CI, 1.09-1.

273 2014 for interstitial lung disease, chronic obstructive pulmonary disease, or pulmonary arterial hyp

274 arthritis; OR 1.71; asthma: OR 1.56; chronic obstructive pulmonary disease: OR 1.65; cancer: OR 1.23;

275 This has been called the asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS), b

276 y (p = 0.88), 30-day readmission for chronic obstructive pulmonary disease (p = 0.83), or hospital le

277 racteristics (older age, female sex, chronic obstructive pulmonary disease; P<0.05 for all), periproc

278 cept for initial diagnosis with more chronic obstructive pulmonary disease patients and less cases of

279 function and remodeling in nonsevere chronic obstructive pulmonary disease patients with a PA:A>1.

280 derately impaired ejection fraction, chronic obstructive pulmonary disease, peripheral vascular disea

281 Chronic obstructive pulmonary disease prevalence was higher amon

282 ividuals except those with asthma or chronic obstructive pulmonary disease produced similar results.

283 ithelial cells from individuals with chronic obstructive pulmonary disease recapitulated features of

284 comitant IL-1beta responses occur in chronic obstructive pulmonary disease, respiratory infections, a

285 Patients with cystic fibrosis, chronic obstructive pulmonary disease, severe asthma, pre-existi

286 sively increased from mild to severe chronic obstructive pulmonary disease severity.

287 ts [5%]), pneumonia (nine [5%]), and chronic obstructive pulmonary disease (six [3%]).

288 ily mortality due to respiratory and chronic obstructive pulmonary disease specifically were positive

289 d for rare variation contributing to chronic obstructive pulmonary disease susceptibility.

290 a candidate susceptibility gene for chronic obstructive pulmonary disease, the physiologic role of t

291 tional study of 13,893 patients with chronic obstructive pulmonary disease treated with noninvasive v

292 diseases, chronic kidney disease and chronic obstructive pulmonary disease were important risk factor

293 rty-five hyperinflated patients with chronic obstructive pulmonary disease were randomized (1:1) to 7

294 importance in mild-to-moderate stage chronic obstructive pulmonary disease where the rate of FEV1 dec

295 nflammatory bowel disease) and lung (chronic obstructive pulmonary disease), where they contribute to

296 elected critically ill patients with chronic obstructive pulmonary disease while also highlighting th

297 ca that included 7,892 patients with chronic obstructive pulmonary disease who enrolled between 1981

298 We enrolled stable outpatients with chronic obstructive pulmonary disease who had a forced expirator

299 Patients with chronic obstructive pulmonary disease, who had at least moderate

300 on and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy